Genzyme Clinical Partners
Executive Summary
Sale of all 200 units of the limited partnership completed, raising approximately $10 mil. to fund development, manufacture and marketing of glucocerebrosidase (GCase) for treatment of Gaucher's disease. The product was developed by scientists at Genzyme and the National Institutes of Health and is currently in Phase II trials at NIH.